DPI formulation containing sulfoalkyl ether cyclodextrin
AssigneeCyDex Pharmaceuticals, Inc.
InventorsJames D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
Life of this patent
Estimating the term…
Loading patent…
AssigneeCyDex Pharmaceuticals, Inc.
InventorsJames D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
Estimating the term…
An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
A composition, comprising solid particles that comprise sulfoalkylether cyclodextrin, wherein the composition comprises less than 8% by weight moisture, has a bulk density of 0.34 g/cc to 0.55 g/cc, and has a micro-flow fractal dimension analysis of about 1.0-1.2, wherein the composition is prepared by a process comprising a spray agglomeration of a feed solution using a spray drier apparatus to form agglomerated particles.
Dependencies are inferred from the claim text.